Mirelle (Ethinylestradiol, Gestodene | Lactose Monohydrate)

Ethinylestradiol and Gestodene, the active ingredients in Mirelle, are a combined oral contraceptive presented as a 30 µg/75 µg tablet for oral use. It prevents pregnancy and helps regulate the menstrual cycle in women of reproductive age by inhibiting ovulation and altering cervical mucus.

GNH USA supplies Mirelle as a licensed, GDP‑compliant international pharmaceutical supplier, delivering quality‑assured medication to hospitals, pharmacies and clinics worldwide while adhering to EU regulatory standards. The company ensures consistent batch release, proper labeling, and secure logistics for global distribution.

Mirelle, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy and manage menstrual disorders.

Contraception: Prevents pregnancy in women of childbearing potential by suppressing ovulation. Menstrual cycle regulation: Provides predictable withdrawal bleeding and reduces menstrual irregularities. Acne management: Improves hormonal acne by reducing androgenic activity in the skin. Endometriosis symptom relief: Decreases pelvic pain associated with endometriosis.

Mirelle may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort of the breasts. - Spotting or irregular bleeding: breakthrough bleeding especially during the first cycles.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism, requiring immediate medical attention. - Stroke or transient ischemic attack: neurological symptoms such as sudden weakness or speech difficulty. - Hepatic adenoma: benign liver tumor, detected through imaging.

Before prescribing Mirelle, clinicians should evaluate individual risk factors and counsel patients on safe use.

Assess cardiovascular risk: evaluate history of thromboembolism, hypertension, or smoking before prescribing. Avoid use in pregnancy: product is contraindicated for pregnant women (Category X). Monitor for signs of thrombosis: educate patients to seek immediate care for leg pain or swelling. Consider drug interactions: review concomitant enzyme‑inducing medications that may reduce efficacy. Counsel on bleeding changes: advise patients about possible spotting or breakthrough bleeding. Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture.

Mirelle can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive effectiveness. - Rifampicin and other strong CYP3A4 inducers: can lower hormone levels, increasing risk of unintended pregnancy. - St. John’s Wort: herbal inducer that may compromise contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Antibiotics such as ampicillin or tetracycline: may slightly decrease hormone levels; advise backup contraception. - Antifungal agents (e.g., fluconazole) and azole antivirals: can increase hormone concentrations, potentially enhancing side effects. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of mood changes; monitor patient.